DD248961A1 - Verfahren zur herstellung wundheilungsfoerdernder praeparationen - Google Patents

Verfahren zur herstellung wundheilungsfoerdernder praeparationen Download PDF

Info

Publication number: DD248961A1
Authority: DD; German Democratic Republic
Prior art keywords: lys; pro; wound; item; derivatives
Prior art date: 1984-05-22

Application number

DD84263249A

Other languages

German (de)

English (en)

Inventor

Klaus-Dieter Jentzsch

Peter Buntrock

Peter Oehme

Andreas Kohl

Klaus Neubert

Original Assignee

Akad Wissenschaften Ddr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-05-22

Filing date

1984-05-22

Publication date

1987-08-26

1984-05-22 Application filed by Akad Wissenschaften Ddr filed Critical Akad Wissenschaften Ddr

1984-05-22 Priority to DD84263249A priority Critical patent/DD248961A1/de

1985-05-21 Priority to EP85106212A priority patent/EP0165492B1/fr

1985-05-21 Priority to AT85106212T priority patent/ATE81464T1/de

1985-05-21 Priority to DE8585106212T priority patent/DE3586752D1/de

1985-06-05 Priority to HU852229A priority patent/HU203981B/hu

1985-06-28 Priority to JP60140659A priority patent/JPH0662428B2/ja

1987-08-26 Publication of DD248961A1 publication Critical patent/DD248961A1/de

Links

230000029663 wound healing Effects 0.000 title claims description 19
238000004519 manufacturing process Methods 0.000 title description 5
230000001737 promoting effect Effects 0.000 title 1
208000027418 Wounds and injury Diseases 0.000 claims abstract description 41
206010052428 Wound Diseases 0.000 claims abstract description 40
108010065920 Insulin Lispro Proteins 0.000 claims abstract description 25
230000035876 healing Effects 0.000 claims abstract description 9
-1 heterocyclic amines Chemical class 0.000 claims abstract description 9
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims abstract description 8
OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 claims abstract description 3
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 3
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 3
229960002591 hydroxyproline Drugs 0.000 claims abstract description 3
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims abstract description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract 6
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims abstract 4
229940081066 picolinic acid Drugs 0.000 claims abstract 2
150000003839 salts Chemical class 0.000 claims abstract 2
AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 claims description 29
238000000034 method Methods 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
108090000765 processed proteins & peptides Proteins 0.000 claims description 6
239000000463 material Substances 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 5
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 4
229920002678 cellulose Polymers 0.000 claims description 4
239000000843 powder Substances 0.000 claims description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
239000000606 toothpaste Substances 0.000 claims description 4
239000003643 water by type Substances 0.000 claims description 4
239000006260 foam Substances 0.000 claims description 3
239000004033 plastic Substances 0.000 claims description 3
229920003023 plastic Polymers 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
239000003212 astringent agent Substances 0.000 claims description 2
239000000022 bacteriostatic agent Substances 0.000 claims description 2
238000004140 cleaning Methods 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
239000004088 foaming agent Substances 0.000 claims description 2
238000009776 industrial production Methods 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
239000007921 spray Substances 0.000 claims description 2
239000002562 thickening agent Substances 0.000 claims description 2
239000003906 humectant Substances 0.000 claims 1
239000002304 perfume Substances 0.000 claims 1
239000004480 active ingredient Substances 0.000 abstract description 20
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 12
JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 abstract description 2
230000004936 stimulating effect Effects 0.000 abstract description 2
102000001189 Cyclic Peptides Human genes 0.000 abstract 1
108010069514 Cyclic Peptides Proteins 0.000 abstract 1
REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 abstract 1
206010063560 Excessive granulation tissue Diseases 0.000 description 17
210000001126 granulation tissue Anatomy 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
241000700159 Rattus Species 0.000 description 12
230000000694 effects Effects 0.000 description 11
241001465754 Metazoa Species 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000003814 drug Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 5
239000002904 solvent Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
108010016626 Dipeptides Proteins 0.000 description 4
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000002537 cosmetic Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000008187 granular material Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000002980 postoperative effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
206010072170 Skin wound Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000012362 glacial acetic acid Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
101800003906 Substance P Proteins 0.000 description 2
208000033809 Suppuration Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000007547 defect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
238000005470 impregnation Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000000047 product Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012353 t test Methods 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
229940058015 1,3-butylene glycol Drugs 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
241000345998 Calamus manan Species 0.000 description 1
108010087806 Carnosine Proteins 0.000 description 1
241000736839 Chara Species 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
241000705082 Sialia Species 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
102400000096 Substance P Human genes 0.000 description 1
241000656145 Thyrsites atun Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000006790 cellular biosynthetic process Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000037313 granulation tissue formation Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
150000007857 hydrazones Chemical class 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
150000002668 lysine derivatives Chemical class 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
150000003147 proline derivatives Chemical class 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000746 purification Methods 0.000 description 1
235000012950 rattan cane Nutrition 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
230000001835 salubrious effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920003051 synthetic elastomer Polymers 0.000 description 1
239000005061 synthetic rubber Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
- A61L2300/214—Amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Materials Engineering (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Birds (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Oral & Maxillofacial Surgery (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)

DD84263249A 1984-05-22 1984-05-22 Verfahren zur herstellung wundheilungsfoerdernder praeparationen DD248961A1 (de)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
DD84263249A DD248961A1 (de)	1984-05-22	1984-05-22	Verfahren zur herstellung wundheilungsfoerdernder praeparationen
EP85106212A EP0165492B1 (fr)	1984-05-22	1985-05-21	Procédé d'obtention des préparations promouvant la guérison des plaies et préparations similaires
AT85106212T ATE81464T1 (de)	1984-05-22	1985-05-21	Verfahren zur herstellung wundheilungsfoerdernder praeparationen und solche praeparationen.
DE8585106212T DE3586752D1 (de)	1984-05-22	1985-05-21	Verfahren zur herstellung wundheilungsfoerdernder praeparationen und solche praeparationen.
HU852229A HU203981B (en)	1984-05-22	1985-06-05	Process for producing pharmaceutical compositions assisting healing of wounds
JP60140659A JPH0662428B2 (ja)	1984-05-22	1985-06-28	創傷治癒を促進する調製物の製造方法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DD84263249A DD248961A1 (de)	1984-05-22	1984-05-22	Verfahren zur herstellung wundheilungsfoerdernder praeparationen

Publications (1)

Publication Number	Publication Date
DD248961A1 true DD248961A1 (de)	1987-08-26

Family

ID=5557208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD84263249A DD248961A1 (de)	1984-05-22	1984-05-22	Verfahren zur herstellung wundheilungsfoerdernder praeparationen

Country Status (6)

Country	Link
EP (1)	EP0165492B1 (fr)
JP (1)	JPH0662428B2 (fr)
AT (1)	ATE81464T1 (fr)
DD (1)	DD248961A1 (fr)
DE (1)	DE3586752D1 (fr)
HU (1)	HU203981B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0490379A3 (fr) *	1990-12-13	1992-06-24	BERLIN-CHEMIE Aktiengesellschaft	Dérivés de diamino-acides et compositions pharmaceutiques
ATE247129T1 (de)	1995-04-11	2003-08-15	Merck & Co Inc	Biologisches verfahren zur herstellung von verbindungen auf der basis der dipeptiden
RU2139085C1 (ru)	1998-06-23	1999-10-10	Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии"	Средство, стимулирующее репаративные процессы, и способ его применения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3862114A (en) *	1971-11-22	1975-01-21	Ici Australia Ltd	Analogs of substance p
DE2945239A1 (de) *	1979-11-09	1981-05-21	Troponwerke GmbH & Co KG, 5000 Köln	Oligopeptide, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
CA1165243A (fr) *	1980-02-19	1984-04-10	Anthony N. Silvetti	Methode et compose pour le traitement des plaies
FR2489145A1 (fr) *	1980-09-04	1982-03-05	Geistlich Soehne Ag	Compositions pharmaceutiques accelerant la guerison de blessures
ZA818919B (en) *	1981-04-13	1982-11-24	Seton Co	Cosmetic and pharmaceutical sheet material containing polypeptides
US4353823A (en) *	1981-09-01	1982-10-12	Chipens Gunar I	Synthetic analog of tuftisin
DD234230A1 (de) *	1983-03-17	1986-03-26	Adw Ddr	Verfahren zur herstellung wundheilungsfoerdernder praeparationen
EP0124317B1 (fr) *	1983-04-27	1990-04-11	Ici Americas Inc.	Dérivés de la proline
CA1267499A (fr) *	1983-07-12	1990-04-03	Cedric H. Hassall	Amides et aldehydes peptidiques
DD222782A1 (de) *	1984-01-16	1985-05-29	Adw Der Ddr Inst F Wirkstoffor	Verfahren zur herstellung stabiler loesungen von undekapeptiden und ihren partialsequenzen
AU569789B2 (en) *	1984-05-03	1988-02-18	Brigham And Women's Hospital	A.c.e. inhibitors to treat renal diseases
US4585757A (en) *	1984-07-27	1986-04-29	Texas Tech University Health Sciences Center	Hypotensive active peptides

1984
- 1984-05-22 DD DD84263249A patent/DD248961A1/de active IP Right Grant
1985
- 1985-05-21 AT AT85106212T patent/ATE81464T1/de not_active IP Right Cessation
- 1985-05-21 EP EP85106212A patent/EP0165492B1/fr not_active Expired - Lifetime
- 1985-05-21 DE DE8585106212T patent/DE3586752D1/de not_active Expired - Fee Related
- 1985-06-05 HU HU852229A patent/HU203981B/hu not_active IP Right Cessation
- 1985-06-28 JP JP60140659A patent/JPH0662428B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HU203981B (en)	1991-11-28
JPS624236A (ja)	1987-01-10
EP0165492A2 (fr)	1985-12-27
DE3586752D1 (de)	1992-11-19
ATE81464T1 (de)	1992-10-15
EP0165492B1 (fr)	1992-10-14
EP0165492A3 (en)	1988-11-02
HUT40916A (en)	1987-03-30
JPH0662428B2 (ja)	1994-08-17

Legal Events

Date	Code	Title	Description
1992-08-27	EPAE	Change in the person, name or address of the patentee
1992-08-27	UW	Conversion of economic patent into exclusive patent
1994-06-23	RPI	Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
2004-04-28	ASS	Change of applicant or owner	Owner name: BERLIN-CHEMIE AG, BERLIN Effective date: 19940331 Owner name: MARTIN-LUTHER-UNIVERSITAET HALLE-WITTENBERG Effective date: 19940331
2004-04-28	IF04	In force in the year 2004	Expiry date: 20040523

Publication	Publication Date	Title
DE69131847T2 (de)	2000-04-27	Verwendung von kupfer enthaltenden wirkstoffen zur beschleunigung der wundheilung
DE60204322T2 (de)	2006-01-26	Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
DE69007592T2 (de)	1994-10-13	Transdermal absorbierbare Dopaminderivate enthaltende Arzneizubereitungen.
DE69620393T2 (de)	2003-01-16	PHARMAZEUTISCHE NICHTINORGANISCHE SALZLÖSUNGEN FÜR ENDONASALE VERABREICHUNG EINEs CALCITONINs
DE69209442T2 (de)	1996-11-14	Dipeptidderivate und sie enthaltende prophylaktische und therapeutische Mittel für Knochenkrankheiten
DE3530046A1 (de)	1986-03-13	Aethylendiaminmonoamid-derivate
CH679779A5 (fr)	1992-04-15
DE292348T1 (de)	1990-02-08	Polycyclische, heterocyclische derivate, verfahren zu deren herstellung sowie deren verwendung in der human- und tiermedizin.
DE69329899T2 (de)	2001-05-23	Behandlung von tropikalischer spastischer Paresis mit Peptide T
DE69322958T2 (de)	1999-05-27	Stabilisiertes somatotropin zur parenteralen verabreichung
WO1995017188A1 (fr)	1995-06-29	Substances actives deuterees en application transdermique
EP0165492B1 (fr)	1992-10-14	Procédé d'obtention des préparations promouvant la guérison des plaies et préparations similaires
EP0450123B1 (fr)	1995-07-05	Composition pharmaceutique pour application topique contenant du diclofenac-sodium
DE1768575C3 (de)	1974-08-01	0-(5-Indanyl)-m,N-dimethylthionocarbanilat, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel
EP0401507A1 (fr)	1990-12-12	Agonistes cycliques de tachykinine
DD234230A1 (de)	1986-03-26	Verfahren zur herstellung wundheilungsfoerdernder praeparationen
DE2723453C2 (de)	1985-07-25	1-Desamino-asparagin&uarr;4&uarr;-D-arginin&uarr;8&uarr;-vasopressin, Verfahren zu seiner Herstellung sowie dieses Peptid enthaltende antidiuretische Arzneimittel
DE2633976A1 (de)	1977-02-10	Tripeptidderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel
EP0028716B1 (fr)	1986-11-12	Peptides augmentant l'effet de motilité et leur utilisation
DE2202176A1 (de)	1972-08-03	Komplexe von biologisch aktiven natuerlichen oder synthetischen Peptiden und/oder Polypeptiden und/oder Eiweissstoffen und/oder deren Derivaten bzw. Salzen,pharmazeutische Praeparate mit einem Gehalt an diesen und Verfahren zur Herstellung derselben
DE69002275T2 (de)	1993-11-04	Stabilisierung von organischen verbindungen.
DE3239710T1 (de)	1983-06-16	Peptide mit nerven-regenerierenden eigenschaften
DE2221281C3 (de)	1979-11-22	Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung
DE3719367A1 (de)	1988-12-29	Verwendung von den stoffwechsel und/oder die struktureigenschaften von kollagen beeinflussenden wirksubstanzen in der kieferorthopaedie
DE2615129B2 (de)	1978-12-14	Tripeptide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen